KNE Stock Overview
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally.
Notes are coming soon
Kane Biotech Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.12|
|52 Week High||CA$0.14|
|52 Week Low||CA$0.075|
|1 Month Change||20.00%|
|3 Month Change||33.33%|
|1 Year Change||-11.11%|
|3 Year Change||-36.84%|
|5 Year Change||33.33%|
|Change since IPO||-93.14%|
Recent News & Updates
|KNE||CA Biotechs||CA Market|
Return vs Industry: KNE matched the Canadian Biotechs industry which returned -11.1% over the past year.
Return vs Market: KNE underperformed the Canadian Market which returned -3.3% over the past year.
|KNE Average Weekly Movement||13.4%|
|Biotechs Industry Average Movement||12.0%|
|Market Average Movement||9.9%|
|10% most volatile stocks in CA Market||19.0%|
|10% least volatile stocks in CA Market||3.9%|
Stable Share Price: KNE is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: KNE's weekly volatility (13%) has been stable over the past year.
About the Company
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name. It also offers scalp care products under the DermaKB brand name, wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, and DermaKB Biofilm brand names.
Kane Biotech Inc. Fundamentals Summary
|KNE fundamental statistics|
Is KNE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|KNE income statement (TTM)|
|Cost of Revenue||CA$1.11m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.034|
|Net Profit Margin||-179.57%|
How did KNE perform over the long term?See historical performance and comparison